Загрузка...
The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes – Is it Advantageous?
Safe and effective therapies for type 2 diabetes are needed to reduce the burden of late complications and costs associated with this chronic disease. Hypoglycaemia and body weight gain are side effects and limitations of the therapy with insulin and/or sulphonylureas. Recently, the combination of g...
Сохранить в:
| Опубликовано в: : | Eur Endocrinol |
|---|---|
| Главный автор: | |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Touch Medical Media
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5983089/ https://ncbi.nlm.nih.gov/pubmed/29872471 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.17925/EE.2014.10.02.98 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|